Erleada Approved for Metastatic Castration-Sensitive Prostate Cancer
Erleada plus ADT achieved statistical significance in meeting both primary end points of OS and rPFS in the phase 3 TITAN study.
Prostate Cancer News
PROSTATE ADVISOR
Prostate Cancer News
Mushrooms May Lower Prostate Cancer Risk
In a study, Japanese men who ate mushrooms each week had lower risk for prostate cancer.
Adding Carboplatin to Cabazitaxel May Slow mCRPC Progression
In a phase 2 trial of men with metastatic castration-resistant prostate cancer, cabazitaxel plus carboplatin significantly prolonged progression-free survival compared with cabazitaxel alone.
Tertiary Gleason Pattern 5 Ups BCR Risk After Radical Prostatectomy
In a study of radical prostatectomy patients with Gleason score 7 prostate cancer, the risk for biochemical recurrence more than doubled in the presence of tertiary pattern 5 disease.
Adjusting the Risk Calculation for Biopsy-Detectable Prostate Cancer
Researchers sought to demonstrate how recalibration of risk stratification tools can improve accuracy and clinical decision making.
Rural Patients May Be Less Likely to Receive Treatment for Prostate Cancer
Simply living in a rural area made it less likely an individual with prostate cancer to receive treatment, with the exception of radiation.
Metastatic Site Predicts Death Risk in Advanced Prostate Cancer
A recent study of men with stage IV prostate cancer revealed that liver-only metastasis is associated with worse cancer-specific and overall survival than bone-only and lung-only metastasis
CVD Prior to Oral Antiandrogen Therapy for Prostate Cancer Increases Mortality Risk
In a study, men who had pre-existing cardiovascular disease prior to taking abiraterone or enzalutamide for advanced prostate cancer had a 16% to 56% increased 6-month risk.
FDA: Entacapone Not Associated With Increased Prostate Cancer Risk
The FDA has concluded that the use of entacapone to treat Parkinson disease (PD) does not increase the risk of developing prostate cancer.
Skeletal-Related Events Common After CRPC Development
Large observational study reveals a 40% cumulative incidence rate of first skeletal-related events following development of castration-resistant prostate cancer.
Surgery May Be Best Option for High-Risk Prostate Cancer With Low PSA
In a study of men with Gleason 8 to 10 prostate cancer and low PSA, radical prostatectomy was associated with better survival odds than external beam radiation therapy with or without brachytherapy.
Prostate Cancer At Biopsy Linked to Low Natural Killer Cells
In a study, natural killer cell activity (NKA) below 200 pg/mL predicted a nearly 5-fold greater risk of having a positive prostate biopsy compared with higher NKA values.
Study Supports Ultra-Hypofractionated Radiotherapy for Prostate Cancer
Ultra-hypofractionated and conventionally fractionated radiotherapy for intermediate- or high-risk prostate cancer are associated with similar 5-year failure-free survival rates, a randomized phase 3 trial found.
Adjuvant Radiotherapy Cuts Prostate Cancer Recurrence Risk
Adjuvant radiotherapy following radical prostatectomy (RP) for PCa with positive margins or extracapsular extension prolongs biochemical recurrence-free survival compared with RP alone, a study found.
FDA Clears Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer
In the phase 3 ARAMIS trial, darolutamide, a nonsteroidal androgen receptor inhibitor, significantly delayed development of metastasis in men with nonmetastatic castration-resistant prostate cancer.
Study: DRE Remains an Important Part of Prostate Cancer Care
Study shows cT2 subclassifications as determined by digital rectal examination, independent predicts mortality risk in men with prostate cancer.
Prostate Cancer ADT Raises Dementia Risk, Study Finds
Androgen deprivation therapy for prostate cancer is associated with a significant 20% increased risk of dementia and 14% increased risk of Alzheimer’s disease, a study found.
Urine Biomarker Helps Classify Risk Level in Prostate Cancer
Urine-derived extracellular vesicle RNA provides diagnostic, prognostic information in prostate cancer.
Routine mpMRI Use Leads to Earlier Treatment of Men on Prostate Cancer AS
Men on active surveillance for prostate cancer progress to treatment sooner if they undergo multiparametric MRI to identify clinically significant tumors.
Prostate Cancer Salvage Cryotherapy May Offer Durable Tumor Control
In a study, patients who underwent salvage cryotherapy for radiorecurrent prostate cancer had cancer-specific and metastasis-free survival rates of 81% and 78%, respectively, at 12 years.
Want to read more?
Please login or register first to view this content.
